Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Treace Medical ConceptsTMCI +3.92%68 Earnings per Share (Diluted) is $-0.93 as of Jun. 2026. GuruFocus rates TMCI with a GF Score™ of 68/100 and a GF Value™ of $6.35 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 661 Medical Devices & Instruments companies, Treace Medical Concepts ranks worse than 72.92% on this metric.
During the past 3 years, the average EPS without NRIGrowth Rate was -8.70% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -49.90% per year.
During the past 7 years, Treace Medical Concepts's highest 3-Year average EPS without NRI Growth Rate was -8.70% per year. The lowest was -112.80% per year. And the median was -60.10% per year.
Treace Medical Concepts (NAS:TMCI) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Treace Medical Concepts Earnings per Share (Diluted) Related Terms
Treace Medical Concepts Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Treace Medical Concepts's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Treace Medical Concepts Earnings per Share (Diluted) Chart
TMCI vs TLSI, CV, RXST: Earnings per Share (Diluted) Comparison
For the Medical Devices subindustry, Treace Medical Concepts's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Treace Medical Concepts PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Treace Medical Concepts's PE Ratio distribution charts can be found below:
* The bar in red indicates where Treace Medical Concepts's PE Ratio falls into.
Treace Medical Concepts Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Treace Medical Concepts's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.93
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.93 mean?
Treace Medical Concepts (TMCI) has a Earnings per Share (Diluted) of $-0.93 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Treace Medical Concepts and its competitors. According to the industry distribution chart, Treace Medical Concepts ranks #482 out of 661 companies in the Medical Devices & Instruments industry, placing it in the top 72.9%.
Is Treace Medical Concepts' Earnings per Share (Diluted) too high?
Treace Medical Concepts' current Earnings per Share (Diluted) is $-0.93. Based on the distribution chart, Treace Medical Concepts ranks #482 out of 661 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Treace Medical Concepts has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Treace Medical Concepts' Earnings per Share (Diluted) compare to TLSI and CV?
According to the Medical Devices & Instruments industry distribution chart, Treace Medical Concepts ranks #482 out of 661 companies for Earnings per Share (Diluted). This places Treace Medical Concepts in the lower half of its industry. The industry median Earnings per Share (Diluted) is 8.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Devices & Instruments company?
The median Earnings per Share (Diluted) among Medical Devices & Instruments companies is 8.00, based on 661 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Treace Medical Concepts and its competitors. For the Medical Devices & Instruments industry, the median Earnings per Share (Diluted) is 8.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Treace Medical Concepts's current Earnings per Share (Diluted) is $-0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Treace Medical Concepts stock overvalued right now?
Based on GuruFocus' analysis, Treace Medical Concepts (TMCI) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.35, compared to a current price of $4.51 — trading 29% below its estimated fair value. The current Earnings per Share (Diluted) is $-0.93. Treace Medical Concepts' overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Treace Medical Concepts (TMCI), the current Earnings per Share (Diluted) is $-0.93 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Treace Medical Concepts (TMCI) Overvalued in 2026?
Based on GuruFocus' analysis, Treace Medical Concepts stock appears to be undervalued.
The current stock price of $4.51 is trading 29% below its estimated GF Value™ of $6.35.
GuruFocus considers Treace Medical Concepts to be Modestly Undervalued.
Key valuation signals for TMCI:
Earnings per Share (Diluted): $-0.93
GF Value™: $6.35 vs. price of $4.51 (29% below fair value)
No single metric tells the full story. See the TMCI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.
68GF Score
Get the complete analysis for TMCI
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TMCI has been successfully added to your 
